Compare General Mills, Inc. (GIS) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Nuvalent Inc — how do they compare? General Mills, Inc. trades at $38.93 (market cap $19.46B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: General Mills, Inc. is the larger of the two by market cap, and General Mills, Inc. pays a 6.69% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| GIS | NUVL | |
|---|---|---|
Market Cap | $19.46B | $9.81B |
Sector | Consumer Staples | Technology |
52-Week High | $51.27 | $123.96 |
52-Week Low | $32.17 | $72.16 |
Enterprise Value | $32.95B | $8.52B |
Dividend Yield | 6.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $36.46, down 0.38% on the day, with a neutral technical signal and mixed earnings history. The stock shows a low P/E of 9.23 and pays a dividend, but faces net income margin pressure at -0.48% for 2026. Recent news highlights partnerships in regenerative agriculture and cost-saving initiatives targeting $3 billion by 2030 to combat soft consumer demand.
Outlook remains cautious with sales pressure expected in 2027, though valuation appears attractive. Key risks include competitive pressures and margin recovery challenges. Analyst consensus is mixed with a hold-heavy rating, suggesting patience for turnaround execution amid economic headwinds.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, amid a pending $124 per share acquisition by GSK. The stock shows a bullish technical signal with moving averages supporting upside, though RSI levels suggest overbought conditions. Fundamentally, the company remains unprofitable with negative ROE and ROA, while cash flow is sustained by financing activities. Recent news is dominated by merger investigations and strategic rationale for the GSK deal.
The investment outlook hinges on the acquisition closing at $124, offering limited upside from current levels. Risks include shareholder litigation and regulatory scrutiny, but the deal provides a clear exit amid ongoing losses. Analyst sentiment is mixed with a slight hold bias, reflecting uncertainty around deal completion and fairness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
